Antitubercular Activity and Synergistic Study of Novel Pyrazole Derivatives

A series of 20 novel pyrazole derivatives were designed and prepared, characterized by ¹H‐NMR, mass spectra (ES‐MS), ¹³C‐NMR, and elemental analysis. The synthesized compounds were then evaluated for their growth inhibitory activity against Mycobacterium smegmatis mc² 155 initially. Rifampicin was used as standard reference. In this screening, derivatives 9 , 10 , and 11 presented superior inhibition compared with standard. Later, these three compounds were exposed for their Mycobacterium tuberculosis H37Rv inhibitory assay using rifampicin as standard reference. Encouraging M. smegmatis mc² 155 inhibition (9 μg/mL), M. tuberculosis H37Rv inhibition (1.9 μg/mL), and synergism with the first‐line and second‐line antibiotics made compound 10 as lead and safe antitubercular agent among the series.